NeoGenomics Inc (NEO)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 43.92% | 41.34% | 36.86% | 38.62% | 41.83% |
| Operating profit margin | -13.94% | -18.21% | -30.04% | -2.06% | -0.48% |
| Pretax margin | -11.92% | -16.41% | -31.26% | -3.11% | -3.16% |
| Net profit margin | -11.92% | -14.87% | -28.30% | -1.72% | 0.94% |
NeoGenomics Inc's profitability ratios demonstrate fluctuations over the years.
- Gross profit margin has shown a slight decrease from 41.83% in 2020 to 38.62% in 2021. However, the margin improved to 43.92% in 2024, indicating an increase in the efficiency of production and pricing strategies.
- Operating profit margin has been negative over the years, with a significant decline from -0.48% in 2020 to -30.04% in 2022. This suggests that the company struggled with controlling operating expenses relative to revenue during these years.
- Pretax margin also remained negative, with the margin worsening from -3.16% in 2020 to -31.26% in 2022. However, there was an improvement to -11.92% in 2024, indicating a decreased proportion of pre-tax losses in revenue.
- Net profit margin experienced fluctuations, with a shift from a positive margin of 0.94% in 2020 to negative margins in subsequent years. The margin improved slightly to -11.92% in 2024, reflecting the company's ability to manage net income relative to revenue more effectively in the later years.
Overall, NeoGenomics Inc has faced challenges in maintaining profitability, particularly in managing operating expenses and generating positive net income. The improvements in gross profit margin and other margins in recent years suggest potential enhancements in operational efficiency and cost management strategies.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -5.62% | -6.41% | -8.80% | -0.53% | -0.22% |
| Return on assets (ROA) | -4.81% | -5.23% | -8.29% | -0.45% | 0.42% |
| Return on total capital | -8.21% | -9.58% | -15.81% | -0.90% | -1.01% |
| Return on equity (ROE) | -8.72% | -9.34% | -14.45% | -0.75% | 0.60% |
Based on the provided data, the profitability ratios of NeoGenomics Inc have shown a declining trend over the years. The Operating Return on Assets (Operating ROA) has decreased from -0.22% in December 31, 2020, to -5.62% in December 31, 2024, indicating a consistent decrease in the company's operating efficiency in generating profits from its assets.
Similarly, the Return on Assets (ROA) has declined from 0.42% in December 31, 2020, to -4.81% in December 31, 2024, signifying a deterioration in the company's overall ability to generate profits relative to its total assets.
The Return on Total Capital has decreased from -1.01% in December 31, 2020, to -8.21% in December 31, 2024, reflecting a negative trend in generating returns for both equity and debt holders.
Lastly, the Return on Equity (ROE) has also witnessed a decline from 0.60% in December 31, 2020, to -8.72% in December 31, 2024, demonstrating a diminishing ability to generate profits for the company's shareholders.
Overall, the declining profitability ratios suggest that NeoGenomics Inc has faced challenges in efficiently utilizing its assets and capital to generate returns for its stakeholders over the analyzed period.